trending Market Intelligence /marketintelligence/en/news-insights/trending/OTet1b__AWAwc25plI3zAg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Synergy's Trulance gains FDA approval for chronic constipation

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Synergy's Trulance gains FDA approval for chronic constipation

The U.S. FDA approved Synergy Pharmaceuticals Inc.'s once-daily 3 milligram Trulance for adults with chronic idiopathic constipation.

The orally administered drug showed improved stool frequency and consistency in two studies compared to placebo. It is the first drug designed to replicate the function of uroguanylin, a gastrointestinal peptide that is thought to stimulate fluid secretion that results in a stool consistency associated with more regular bowel function, the company said in a news release.

Trulance will be available in the U.S. in the first quarter.

The company also said it completed two phase 3 trials for the drug to treat irritable bowel syndrome with constipation and plans to file a new drug application supplement later this quarter.